This open label, two period, crossover study will evaluate the safety and the effect of food on the pharmacokinetics of RO5428029 in healthy volunteers. In a crossover design, healthy subjects will be randomized to receive a single oral dose of RO5428029 with or without food, with a washout period of at least 7 days between dosing and a follow-up of 7 to 10 days after last dose. Anticipated time on study will be up to 21 days.

Inclusion Criteria:

• Healthy volunteers, 18 to 60 years of age inclusive
• Body mass index (BMI) between 18 and 29.9 kg/m2, inclusive, and a minimum weight of 45 kg
• Female subjects must be surgically sterile or post-menopausal
• Male subjects and their partners of child-bearing potential must use 2 methods of contraception (one of which a barrier method) for the duration of the study and for at least 70 days after the last dose

Exclusion Criteria:

• Pregnant or lactating women, and male partners of women who are pregnant or lactating
• Women with reproductive potential
• History (within 3 months of screening) of alcohol consumption exceeding 2 standard units per day on average; alcohol consumption will be prohibited at least 48 hours before screening
• Positive test for drugs of abuse
• History or symptoms of any significant disease
• Positive for HIV, hepatitis B or hepatitis C infection
• Participation in an investigational drug or device study within 3 months prior to screening